Josephine Anne Lucero

Association of abnormal coagulation parameters with adverse clinical outcomes among patients with moderate to severe SARS-CoV-2 infection

Geraldine T. Zamora, Evelyn O. Salido, Jaime Alfonso Aherrera, Deonne Thaddeus V. Gauiran et autres

Introduction: This study aimed to determine the association between thrombophilia and adverse clinical outcomes among hospitalized patients with moderate to severe COVID-19 in a tertiary COVID-19 referral hospital. Materials and Methods: This is a cross-sectional study among adult patients hospitalized with moderate …

ph (code pays fourni par la source)

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, María Agustina Perusini, Aniket Bankar, Marta Davidson et autres

Abstract Introduction Measurable residual disease (MRD) monitoring is informative for long-term prognosis in patients with acute myeloid leukemia (AML) at the time of remission assessment. While next-generation sequencing-based MRD monitoring in FLT3-ITD AML is being explored for clinical use, its adoption is …

ca (code pays fourni par la source)

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Gail J. Roboz, Tom Reuvekamp, Jacqueline Cloos, Malte von Bonin et autres

Abstract Background The treatment landscape of acute myeloid leukemia (AML) is rapidly evolving due to advances in novel targeted agents, lower-intensity treatments, and allogeneic stem cell transplantation. Simultaneously, technologic advances are allowing increasingly sensitive detection of measurable residual disease (MRD) to guide …

us, nl, de, it, br, pt, ca, gr, es, fr (code pays fourni par la source)

Effects of Structured Exercise Programs on Self-Reported Health-Related Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Carl Lawrence C Arenos, Franessa Ysabel Dianne Chan Huan-Jacinto, Josephine Anne Lucero, Frederic Ivan L. Ting et autres

Current treatments for metastatic non-small cell lung cancer (NSCLC) have improved survival but remain non-curative, primarily aiming to control disease and to extend life. Structured exercise has demonstrated clinical and quality-of-life benefits in early-stage NSCLC. This systematic review assesses the impact of …

ph, ca (code pays fourni par la source)

Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

María Agustina Perusini, Claire Andrews, Eshetu G. Atenafu, Vikas Gupta et autres

ca, ie (code pays fourni par la source)

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation

Josephine Anne Lucero, Muhned Alhumaid, Igor Novitzky‐Basso, José‐Mario Capo‐Chichi et autres

ca, sa (code pays fourni par la source)

Clinico-pathologic Profile of Filipino Patients Diagnosed with Diffuse Large B-Cell Lymphoma, Germinal Center or Non-germinal Center Subtype Treated in a Public Tertiary Hospital from 2016 to 2021

Jonathan Emmanuel G Cancio, Karen Damian, Emilio Q Villanueva, Josephine Anne Lucero et autres

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). Classification of DLBCL is often based on the cell of origin (COO), distinguishing between germinal center B-cell (GCB) and non-GCB subtypes. Although not yet recognized as a …

ph, us (code pays fourni par la source)

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

Eshrak Al‐Shaibani, María Agustina Perusini, Josephine Anne Lucero, Gopila Gupta et autres

Introduction: Nilotinib (NIL) is a potent second-generation tyrosine kinase inhibitor (TKI) approved for the treatment of newly diagnosed chronic myeloid leukemia (CML) patients (pts) in chronic phase, but reported to increase long-term toxicity such as cardiovascular (CV) risks. The ENESTfreedom study (Leukemia …

ca (code pays fourni par la source)

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al‐Shaibani, María Agustina Perusini et autres

Introduction Recent advances in genomics in chronic myeloid leukemia (CML) patients (pts) provide new insights in understanding somatic mutation (SM) and their prognostic implications following tyrosine kinase inhibitor (TKI) therapy. DNMT3A, TET2, or ASXL1 (DTA) mutations are most frequently detected following TKI …

ca, cz (code pays fourni par la source)

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Davidson, Guillaume Richard‐Carpentier et autres

Introduction Measurable residual disease (MRD) monitoring is predictive in acute myeloid leukemia (AML). Assessment of FMS3-like tyrosine kinase-3 in-frame internal tandem duplications (FLT3-ITD) is usually performed at diagnosis by polymerase chain reaction (PCR). Due to its relative lower sensitivity of 2%, FLT3-ITD …

ca (code pays fourni par la source)

PB2248: BONE MARROW NECROSIS: RARE PRESENTATION OF CHRONIC MYELOID NEOPLASMS SYSTEMIC REVIEW AND CASE REPORT

Verna Cheung, Josephine Anne Lucero, Marta Davidson, Hassan Sibai

Topic: 16. Myeloproliferative neoplasms - Clinical Background: The prevalence of bone marrow necrosis (BMN) with hematological malignancy (HM) is 0.3% to 2.2%. Very rarely, BMN has been reported with chronic myeloid neoplasms (CMN). BMN is defined as necrosis of myeloid tissue and …

ca (code pays fourni par la source)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Josephine Anne Lucero, Salman Al-Harbi, Karen Yee

Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classification of …

ca (code pays fourni par la source)